Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.89 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL990691 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2442893 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL236214 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL990690 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL617118 | 1.00 | OPRD1 (0.98) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8512218 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29317 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL1559600 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2030143 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL940320 | 0.99 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524277-B2 | Extended release dosage form | ALZA CORPORATION (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110229533-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 2011-09-22 | — | — | US | disclosed |
| EP-1600154-B1 | Osmotic extended-release dosage form | ALZA CORP (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20070128279-A1 | Extended Release Dosage Form | ALZA CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| EP-1600154-A1 | Osmotic extended-release dosage form | Alza Corporation (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1059916-B1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1384471-A1 | Osmotic extented-release dosage form | ALZA CORPORATION (US) | 2004-01-28 | — | — | EP | disclosed |
| US-6245357-B1 | CONTAINING HYDROMORPHONE, ACETAMINOPHEN AND CARRIER | ALZA CORPORATION | 2001-06-12 | — | — | US | disclosed |
| EP-1059916-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044591-A1 | EXTENDED RELEASE DOSAGE FORM | ALZA CORPORATION (US) | 1999-09-10 | — | — | WO | disclosed |